Childhood cancer research gets million dollar boost

Published at Dec 16, 2019, in Buy and Cell

Australian Lions Childhood Cancer Research Foundation has announced it will provide $1.05 million of funding to the Telethon Kids Institute.

The funding will support the Telethon Kids Cancer Centre’s vital research aimed at improving survival rates, longevity and quality of life for children with cancer.

The Telethon Kids Institute is one of Australia’s largest independent health and medical research institutes, committed to discovering new and effective ways to enhance children’s health and wellbeing.

“At Australian Lions Childhood Cancer Research Foundation we believe every child deserves a chance at a healthy life,” Australian Lions Childhood Cancer Research Foundation Chairperson John Thorpe said. “We are very proud to be providing $1.05 million worth of funding to Telethon Kids.”

Chair of the Telethon Kids Institute, the Hon. Julie Bishop, said they are excited to be partnering with such a well-respected, community-oriented organisation like Lions Australia.

“We are so grateful for Australian Lions Childhood Cancer Research Foundation’s support,” Ms Bishop said. “This $1.05 million in funding will enable the Telethon Kids Cancer Centre to continue its leading research into childhood cancer – particularly in the area of cancer immunotherapy, which focuses on supercharging the body’s natural defences to destroy cancer cells.”

Headquartered in Perth at the Perth Children’s Hospital, the Telethon Kids Institute has an international reputation for the work it has undertaken over the past 30 years to prevent, cure or reduce harm from chronic, infectious and other severe diseases, neuro-developmental disorders, and mental health challenges that affect children.

Telethon Kids cancer researcher Dr Rishi Kotecha with Australian Lions Childhood Cancer Research Foundation Trustee Peter Lamb.
Telethon Kids cancer researcher Dr Rishi Kotecha with Australian Lions Childhood Cancer Research Foundation Trustee Peter Lamb.

Mr Thorpe described cancer immunotherapy as one of the most exciting and promising cancer treatments being developed, particularly for childhood cancer.

“It is our hope that this work will benefit kids all over Australia and beyond,” he said. “More than 800 children aged 0-14 years are diagnosed with cancer in Australia each year. Many of these cancers are aggressive and hard to treat and we are losing too many young lives.”

“Although survival rates have improved greatly for some, most cancers take a toll on young people’s lives and often side effects of treatment can be serious and lifelong.”

“Telethon Kids Cancer Centre’s research into cancer immunotherapy is focused on finding ways to help these children’s immune systems fight cancer cells. This will be revolutionary in the treatment of childhood cancer.”

Professor Terrance Johns, Head of the Telethon Kids Cancer Centre, said that as one of Australia’s only comprehensive, paediatric cancer immunotherapy centres, the Telethon Kids Cancer Centre was making its mark on medical research.

“The Centre is on a mission to prevent paediatric disease and improve the wellbeing of children with cancer. We bring together leading researchers and oncologists focused on developing therapies that destroy cancer cells, while minimising the side effects to children’s short and long-term health,” Professor Johns said.

The $1.05 million of funding to Telethon Kids Institute builds on the Australian Lions Childhood Cancer Research Foundation’s long history in supporting leading and innovative research into childhood cancer.

S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.

Conflict of Interest Notice

S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.

Publishers Notice

The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.

Australian ASX Small Cap stocks | Why Finfeed.com is Australia’s leading small cap publication

Founded seven years ago, Finfeed.com is Australia’s leading and longest standing website for investor and finance news, education and expert opinion.

Published by StocksDigital, Finfeed was created to report daily on the comings and goings of ASX listed stocks in the small cap market.

As the first digital publication dedicated specifically to this space, Finfeed soon became the most trusted publication in the market, quickly garnering over two million page views – a number that continues to rise.

Finfeed.com provides its readers with informative articles that tackle the latest in market moving #ASX small cap news, plus exclusive content you won’t find anywhere else. It is aimed at those with an interest in investing, market education, company performance, start-ups and much more.

Finfeed.com is the only media organisation operating under the strength of a Financial Services License and is backed by leading journalists and analysts all with brands of their own.

The website aims to inform, educate and entertain with content that drills down into the heart of financial matters.

Finfeed is a leading source of investor and market information, with everything investors need to know about how to invest written in a way that anyone can understand. 

Over the years, the website has expanded beyond exclusively reporting on small caps, to profile Australia’s leading ASX listed small, mid and large caps as well as some of the country’s most successful CEOs and business leaders to find out what makes them tick.

Every day you will find fresh content covering:

Fast Facts

Over 4,000 articles published

Over 2.3 Million Page Views and counting

Over 10,000 followers on social media

Subscriber list growing by 2% monthly

Thanks for subscribing!

X